Peter Forsyth is a Neurology physician affiliated with Moffitt Cancer Center. OpenAlex indexes 501 publications with 25,690 citations (h-index 81); ClinicalTrials.gov lists 7 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Neurology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
2 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
77.1%Other antiepileptics43.8%Lacosamide64%Levetiracetam36%Part D<11 patientsBenzodiazepine21.9%Lorazepam100%Part D≥11 patients+ 1 more class in this area
Sensory organs
11.5%Corticosteroid11.5%Hydrocortisone100%Part D<11 patientsMetabolism & gastrointestinal
11.5%Serotonin-3 Receptor Antagonist11.5%Ondansetron Odt100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence.
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$657,121R01CA289387 - Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence.
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$657,121R01CA289387 - Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases
H. Lee Moffitt Cancer Ctr & Res Inst
FY2018$224,460R21CA216756
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Eric Haura, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”